Publication Tawinprai K, Expert Rev Vaccines, 2022
Dates: 2021-08-09 to 2021-08-13
Funding: Public/non profit (Chulabhorn Royal Academy and National Vaccine Institute)
Conflict of interest: no COI
Single center / Thailand |
Follow-up duration (months): 0.5
1 IM dose of 5 x 10^10 vp AZD1222 (booster), 2-4 months after 2 prime doses of CoronaVac.
1 IM dose of 4 mcg BBIBP-CorV (booster), 2-4 months after 2 prime doses of CoronaVac.
|Characteristics of participants|
Type of participants: Adults without active underlying disease
Pregnant women: 0
Immunocompromized patients: 0
Age range: NR
|Description of participants|
Adults, including elderly, without active underlying disease and with no history of COVID-19, who completed 2 doses of CoronaVac, in a single centre in Thailand.
|In the register|
Outcome Name: Humoral immunity 2 weeks after third dose; Metric / Method of measurement: Double antigen technique for detection of Antibody level of total antibody of spike protein of SARS-CoV-2; Time point: 2 weeks after the third dose of the vaccine
|In the report|
Ratio of the geometric mean concentration (GMR) of the total anti-RBD antibody concentration post-vaccination compared with that pre-vaccination in each vaccine group.
|Risk of bias
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
|General comment||In addition to the published article, the study registry was used in data extraction and risk of bias assessment. The protocol and statistical analysis plan were not available. There were no important differences between protocol/registry and published report in population, procedures, interventions or outcomes. The target sample size specified in the registry (n=80) was achieved (n=81).|